An Overview of the Diagnosis and Treatment of Erectile Dysfunction
- 1 January 2006
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 66 (18) , 2339-2355
Abstract
Epidemiological studies have demonstrated an age-stratified increase in the incidence and prevalence of erectile dysfunction (ED). There is a greater degree of openness today when discussing sexual matters and more information on the treatment of ED is available to the public through the media. Quality-of-life issues are now a matter of great importance to the aging population. Men and their partners are no longer prepared to merely accept ED as a natural consequence of aging. The advent of a simple and effective oral therapy for ED has also indirectly fuelled the increase in treatment-seeking behaviour among men. Despite great strides in research into ED, our knowledge and understanding of the pathophysiological mechanisms is still in its infancy. As a result, we are able to treat only the symptom of ED rather than prevent it. Common diseases found in the population, such as diabetes mellitus and coronary artery disease appear to be risk factors for the development of ED. Therefore, physicians need to identify any underlying co-existing organic diseases in their patients presenting with ED. Whenever possible, patients are encouraged to attend their consultation sessions with their partners because ED is a condition affecting ‘the couple’ and not just the man. Psychogenic aspects of ED should also be explored during the consultation. Efforts need to be made to uncover and address the presence of any psychological stressors, if necessary with the help of a psychosexual therapist. The first-line treatment of ED is oral phosphodiesterase-5 inhibitors. For those who do not respond to oral therapy, there is no defined ‘step-ladder’ escalation in alternative therapy. It is up to the physician to discuss the options with the patient or couple and reach a decision based on their preference.Keywords
This publication has 83 references indexed in Scilit:
- Evaluating Preference Trials of Oral Phosphodiesterase 5 Inhibitors for Erectile DysfunctionEuropean Urology, 2006
- RANDOMIZED STUDY OF TESTOSTERONE GEL AS ADJUNCTIVE THERAPY TO SILDENAFIL IN HYPOGONADAL MEN WITH ERECTILE DYSFUNCTION WHO DO NOT RESPOND TO SILDENAFIL ALONEJournal of Urology, 2004
- Erectile dysfunction: management updateCanadian Medical Association Journal, 2004
- Tadalafil has No Detrimental Effect on Human Spermatogenesis or Reproductive HormonesJournal of Urology, 2003
- LONG-TERM EXPERIENCE WITH SALVAGE OF INFECTED PENILE IMPLANTSJournal of Urology, 2000
- AMS Three–Piece Inflatable Implants for Erectile Dysfunction: A Long–Term Multi–Institutional Study in 200 Consecutive PatientsEuropean Urology, 2000
- Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novelBJU International, 1999
- SildenafilDrugs, 1999
- Treatment of Men with Erectile Dysfunction with Transurethral AlprostadilNew England Journal of Medicine, 1997
- Vacuum Constriction Devices: Second‐line Conservative Treatment for ImpotenceBritish Journal of Urology, 1992